With glucocorticoid replacement
GH-axis stimulation can reduce cortisone-to-cortisol conversion and unmask or worsen adrenal insufficiency.
Interaction evidence sourceGH secretagogue
Prepared by the ezGLP team. Sources last checked .
Routes represented in the knowledgebase: Subcutaneous (SubQ).
Tesamorelin is listed in the ezGLP knowledgebase under GH secretagogue. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
Common or reported: edema, joint or muscle pain, tingling or carpal-tunnel symptoms, headache, injection-site reactions.
Serious or important: intracranial hypertension, glucose intolerance or diabetes, adrenal insufficiency, pancreatitis, malignancy-related warnings.
Safety evidence sourceThese are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
GH-axis stimulation can reduce cortisone-to-cortisol conversion and unmask or worsen adrenal insufficiency.
Interaction evidence sourceGH-axis stimulation can reduce insulin sensitivity and alter glucose control.
Interaction evidence sourceDuplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.
Interaction evidence sourceSummarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.